Accueil / Communiqués / ArQule To Report First Quarter 2017 Financial Results On May 3, 2017

ArQule To Report First Quarter 2017 Financial Results On May 3, 2017

Wednesday, April 19th 2017 at 11:00am UTC

Inc. (Nasdaq: ARQL) today announced it will report financial results for
the first quarter 2017 before the market opens on Wednesday, May 3,
2017. The Company will hold a conference call and webcast on the same
day at 9:00 a.m. ET to discuss these results and provide a general
business update.

The live webcast can be accessed in the “Investors and Media” section of
our website,,
under “Events
& Presentations
.” You may also listen to the call by dialing
(877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A
replay will be available two hours after the completion of the call and
can be accessed in the “Investors & Media” section of our website,,
under “Events
and Presentations

About ArQule

is a biopharmaceutical company engaged in the research and development
of targeted therapeutics to treat cancers and rare diseases. ArQule’s
mission is to discover, develop and commercialize novel small molecule
drugs in areas of high unmet need that will dramatically extend and
improve the lives of our patients. Our clinical-stage pipeline consists
of four drug candidates, all of which are in targeted, biomarker-defined
patient populations, making ArQule
a leader among companies our size in precision medicine. ArQule’s
proprietary pipeline includes: ARQ 087, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor receptor
(FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology
indications; ARQ 092, a selective inhibitor of the AKT serine/threonine
kinase, in phase 1 for multiple oncology indications as well as
ultra-rare Proteus syndrome, in partnership with the National Institutes
of Health (NIH); ARQ 751, a next generation AKT inhibitor, in phase 1
for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone
analog being evaluated as a promoter of NQO1-mediated programmed cancer
cell necrosis, in phase 1/2 in multiple oncology indications in
partnership with the University of Texas Southwestern Medical Center. In
addition, we have advanced ARQ 531, an investigational, orally
bioavailable, potent and reversible inhibitor of both wild type and
C481S-mutant BTK, through toxicology testing and plan to initiate a
phase 1 trial by the third quarter of 2017. ArQule’s current discovery
efforts are focused on the identification and development of novel
kinase inhibitors, leveraging the Company’s proprietary library of
compounds. You can follow us on Twitter
and LinkedIn.


Dawn Schottlandt, 781-994-0300
Sr. Director, Investor
Relations/Corp. Communications

Source: ArQule

Voir aussi

PAREXEL International Receives Shareholder Approval for Proposed Acquisition by Pamplona Capital Management

Monday, September 18th 2017 at 1:00pm UTC BOSTON–(BUSINESS WIRE)– PAREXEL International Corporation (NASDAQ: PRXL) (« PAREXEL » …

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
Retrouvez nous sur
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...